![](images/graphics/blank.gif)
B-cell acute lymphoblastic leukemia
-
The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ Bcell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.
10p
vianrose2711
27-04-2021
9
1
Download
-
TP53 mutations occur in only about 3% of primary and 10–20% of relapse B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). However, alternative mechanisms may contribute to functionally impairing the p53 pathway in the absence of a mutation.
9p
vikuala271
13-06-2020
7
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)